Jafron Biomedical Co.,Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.
September 22, 2021 at 12:00 pm EDT
Share
Jafron Biomedical Co.,Ltd. (SZSE:300529) commences a share repurchases on September 22, 2021, under the program mandated by the shareholders in the Extraordinary General Meeting held on September 14, 2021. As per the mandate, the company is authorized to repurchase up to CNY 500 million worth of its A shares. The shares will be repurchased at a price not more than CNY 80 per share. The company will use own funds to repurchase its shares, which will be used in the future for the company to implement employee stock ownership plans, equity incentives, or to convert corporate bonds issued by listed companies that can be converted into stocks. The authorization will be valid for a period of 6 months.
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
Jafron Biomedical Co.,Ltd. commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.
JAFRON BIOMEDICAL CO.,LTD. 
